advertisement
Abstract #104635 Published in IGR 23-2
Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury
Moos WH; Faller DV; Glavas IP; Harpp DN; Kamperi N; Kanara I; Kodukula K; Mavrakis AN; Pernokas J; Pernokas M; Pinkert CA; Powers WR; Sampani K; Steliou K; Tamvakopoulos C; Vavvas DG; Zamboni RJ; Chen XBiochemical Pharmacology 2022; 203: 115168
Pathological deterioration of mitochondrial function is increasingly linked with multiple degenerative illnesses as a mediator of a wide range of neurologic and age-related chronic diseases, including those of genetic origin. Several of these diseases are rare, typically defined in the United States as an illness affecting fewer than 200,000 people in the U.S. population, or about one in 1600 individuals. Vision impairment due to mitochondrial dysfunction in the eye is a prominent feature evident in numerous primary mitochondrial diseases and is common to the pathophysiology of many of the familiar ophthalmic disorders, including age-related macular degeneration, diabetic retinopathy, glaucoma and retinopathy of prematurity - a collection of syndromes, diseases and disorders with significant unmet medical needs. Focusing on metabolic mitochondrial pathway mechanisms, including the possible roles of cuproptosis and ferroptosis in retinal mitochondrial dysfunction, we shed light on the potential of α-lipoyl-L-carnitine in treating eye diseases. α-Lipoyl-L-carnitine is a bioavailable mitochondria-targeting lipoic acid prodrug that has shown potential in protecting against retinal degeneration and photoreceptor cell loss in ophthalmic indications.
Department of Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, CA, USA. Electronic address: walter.moos@ucsf.edu.
Full article